
|Webinars|May 6, 2022
Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care? Part 2
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
Advertisement
In this webinar from The American Journal of Managed Care®'s Oncology Value Coalition, experts from The US Oncology Network discussed the future of value-based cancer care.
Despite many successes, the Oncology Care Model (OCM) is set to expire in July 2022, with no replacement on the horizon. That doesn't mean the lessons of the OCM will be forgotten, but continuing the quality care efforts will be difficult. How will practices continue team-based care, patient navigation, and other enhanced services?
The speakers were:
- Rhonda Henschel, senior director of payer solutions, The US Oncology Network
- Ben Jones, vice president of government relations and public policy
McKesson Specialty Provider Organization, The US Oncology Network - Stuart Staggs, senior director of strategic programs, The US Oncology Network
- Lalan Wilfong, MD,vice president of payer relations and practice transformation, The US Oncology Network
In segment 2, they discussed value for commercial payers and employers.
Advertisement
Related to this article

In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.

Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
3
Early-Onset Cancers Often Found Late as Screening Gaps Persist
4
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
5

